Indeed, although immunotherapy targeting the PD-1/PD-L1 axis shows great promise for ccRCC, only 15–25% of patients respond when given it as a monotherapy [60], and there is increasing movement towards combination therapy of antiangiogenic agents and immunotherapy [59,61,62,63,64]. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.